These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 33371161

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J, Song Q, Guo F, Du R, Fang H, Kang J, Lu Z.
    Nucl Med Commun; 2022 Jun 01; 43(6):717-724. PubMed ID: 35354781
    [Abstract] [Full Text] [Related]

  • 24. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
    Önner H, Eren OÖ, Körez MK, Yilmaz F, Kara Gedik G.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023 Jun 01; 42(5):319-324. PubMed ID: 37030597
    [Abstract] [Full Text] [Related]

  • 25. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A.
    Radiology; 2016 Jul 01; 280(1):220-9. PubMed ID: 26854705
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors.
    Nasir Z, Mahmood T, Adel H, Nausheen S, Hamid S, Sattar A, Manohar M.
    Cureus; 2019 Aug 18; 11(8):e5422. PubMed ID: 31632874
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
    Dhull VS, Sharma P, Sharma DN, Maharjan S, Suman Kc S, Patel C, Bal C, Kumar R.
    Int J Gynecol Cancer; 2014 Feb 18; 24(2):312-20. PubMed ID: 24407578
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal.
    Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, Darcourt J, Comte V, Humbert O.
    Eur J Nucl Med Mol Imaging; 2024 Oct 18; 51(12):3696-3708. PubMed ID: 38896129
    [Abstract] [Full Text] [Related]

  • 38. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
    Tao X, Li N, Wu N, He J, Ying J, Gao S, Wang S, Wang J, Wang Z, Ling Y, Tang W, Zhang Z.
    Eur J Nucl Med Mol Imaging; 2020 May 18; 47(5):1209-1219. PubMed ID: 32043180
    [Abstract] [Full Text] [Related]

  • 39. Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer.
    Tang S, Zhang Y, Li Y, Zhang Y, Xu Y, Ding H, Chen Y, Ren P, Ye H, Fu S, Lin S.
    Front Immunol; 2023 May 18; 14():1034416. PubMed ID: 36860861
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.